Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
The purpose of this study is to determine if residual weakness after weight loss surgery
 leads to an increased risk of respiratory complications in the postoperative period.
Patients interested in bariatric surgery would contact Dr. Marema or Dr. Koppman. Dr. Marema
 and Dr. Koppman will determine, if patients qualify for bariatric surgery. Patients will
 undergo a thorough preoperative workup. After optimization of all medical conditions patients
 would be scheduled for bariatric surgery. This is our current clinical practice.

 One of the investigators would determine if a patient would qualify for the study. Then one
 of the investigators would approach the patients and explain the study in detail. Patients
 would be able to give informed consent or refuse to participate.

 Patients refusing to participate in the study will need to sign a consent that data will be
 collect for internal quality control (IRB approval on file). The patients would be scheduled
 for bariatric surgery and be treated per our current clinical practice.

 All patients would undergo a similar anesthetic. At the end of the procedure, before the NMBA
 reversal agent is given, the patients would be randomized to either the control or study
 group.

 Intraoperative Anesthestic Management:

 Patients receive sedative medication, typically midazolam 2-4mg iv. An infusion of
 dexmedetomidine will be started. Patients younger than 65 years will receive a loading dose
 of 1mcg/kg over 10 minutes. In patients older than 65 years 0.5 mcg/kg will be given as a
 loading dose. After administration of the loading dose an infusion will be continued
 throughout the duration of the surgery at a dose of 0.1-1mcg/kg/h. The infusion will be
 discontinued at the end of surgery. General anesthesia will be induced with a single dose of
 Lidocaine and Propofol with either Succinylcholine or Rocuronium given to provide intubating
 conditions. The patient's trachea will be intubated and mechanical ventilation started.
 General anesthesia will be maintained with an infusion of dexmedetomidine and propofol and
 titrated to the desired level of anesthesia. Ketamine will be administered as an adjunctive
 analgesic at a dose of 0.5 mg/kg. Neuromuscular blockade appropriate for surgical conditions
 will be provided by either the long acting neuromuscular blocking agents (NMBA), Rocuronium
 or Vecuronium, at the anesthesia providers discretion. At the conclusion of the operation the
 degree of NMB/paralysis will be assessed and a NMBA reversal administered (see detailed
 description below). Patients will be extubated after the end of surgery and transported to
 the PACU.

 Monitoring of Neuro-Muscular Block (NMB or paralysis):

 A signal is send from the brain to the muscle via an electrical impulse through a nerve.
 Electrical impulses can be applied externally to provoke muscle contraction. This technique
 is used to monitor the degree of paralysis induced by administration of NMBA.

 NMBAs interrupt impulses or signals from the nerve to the muscle. External stimulation also
 does NOT lead to a muscle contraction in a paralyzed patient. Once the body metabolizes the
 NMBA the signal can travel again from the nerve to the muscle and provoke a muscle twitch.
 This recovery is gradual meaning that the initial twitches are weak and gradually get
 stronger. Also muscle fatigue faster with NMBA present (fade). This means that with similar,
 repetitive stimulation the twitch gets weaker. In anesthesia these attributes are examined to
 determine the degree of muscle relaxation and, or if at all, a dose of NMBA reversal can be
 given and what the appropriate dose should be.

 There are two different ways of monitoring NMB: qualitative and quantitative.

 Qualitative (current management) - Control Group:

 The paralysis can be monitored tactile (feeling) or visual (seeing) to determine the twitch
 strength and the fade of repetitive stimulation. This determines the dose of reversal. After
 the reversal is given the anesthesia provider waits further to determine that the twitches
 are strong and there is no more fade. Then the patient will be extubated and transported to
 the PACU.

 Quantitative (proposed management) - Study Group:

 The paralysis would be monitored with a sensor (acceleromyography - AMG) that measures the
 twitch-strength after the ulnar nerve was stimulated (detailed explanation below). This
 objective data allows the anesthesia provider to titrate the NMBA reversal to best effect to
 assure adequate return to full muscle strength. Then the patient will be extubated and
 transported to the PACU.

 AMG:

 The technical term for the way of assessing the muscle contraction is called
 acceleromyography (AMG). AMG relies on 2 stimulating electrodes usually placed along the
 ulnar nerve at the wrist and a sensor that is placed in the groove between the thumb and the
 index finger; the sensor detects the acceleration of movement (bending) that is produced by
 the thumb in response to electrical stimulation of the ulnar nerve (TOF-Watch® SX Monitor).
 When the thumb contracts and accelerates the piezoelectric sensor, the degree of movement is
 sensed, and it is converted into electrical signals that are proportional to the force of
 thumb contraction. AMG can yield signals that can be measured and that can give an indication
 of the degree of neuromuscular block.

 Randomization:

 Patients will be randomized at the time when NMB can be reversed. Depending on the result the
 patient will be in the study or control group. Randomization will be done by a statistical
 software called R or an online web program called random.org.

 Power analysis:

 reduction from risk of a respiratory event in the postoperative period from 30% to 17.5% with
 an alpha of 0.05 and a power of 0.8 allocation approximately even in both groups (n1=n2)
 total sample size n=362, critical z=1.96, calculated by G Power 3

 Data analysis:

 primary Intention to treat analysis to reflect clinical reality, secondary analysis as per
 protocol

 Definition of RE, adapted from Ziemann-Gimmel et. al. f1000research 2012 and Murphy et. al.
 Anesth Analg 2010;107(1):130-7

 Protocol Changes:

 Randomization occurs as described above at the time when the anesthesia provider feels
 "comfortable" based on the qualitative measurement of the TOF. If patient is randomized to
 the intervention group (quantitative measurement) reversal will be given based on the AMG
 (TOF Watch).

 The change to the protocol:

 1. If 30 minutes after the above time point no adequate AMG measurement is obtained
 reversal will be administered.

 2. If after administration of reversal 30 minutes have elapsed and the AMG is less than 90%
 patients will be emerged from anesthesia.

 3. administration of reversal in the intervention group will occur only after at least 4
 twitches are measured consistently with the AMG. The previous suggested time-point
 suggested by the review article by Brull and Murphy where it can be given after 3
 twitches seems to be to early and patients may not regain a TOF greater than 90%.

 Dealing with missing TOF data:

 If patients were randomized they will be analyzed in the according group (ITT). linear
 regression after log transformation will be done with the existing traces. There will be a
 best-/worst case scenario for sensitivity analysis. Missing values will be randomly sample
 and five scenarios will be analyzed to determine any impact (sensitivity analysis).
 (Imputation)

 Also the best/worst case scenario will be analyzed:

 best case: patients regain a TOF of 100% worst case: TOF is reduced by 5% from last
 measurement - it is physiologically unlikely that the TOF will be reduced to a greater extend
 over time.
Inclusion Criteria:

 - All patients scheduled for bariatric surgery at Flagler Hospital will be included after
 written and informed consent.

 Exclusion Criteria:

 - Patients will be excluded from the study if they don't consent to participate in the
 study. Patients allergic to any of the study medication will be excluded.